|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 162.81 USD | -0.11% |
|
-2.33% | +12.58% |
| Mar. 13 | Trump's tariffs and threatened trade actions | RE |
| Mar. 12 | Lilly, J&J boosted spending on executive security after UnitedHealth shooting | RE |
| Capitalization | 392B 360B 347B 303B 564B 34,081B 621B 3,976B 1,507B 14,375B 1,469B 1,440B 58,132B | P/E ratio 2025 * |
19.1x | P/E ratio 2026 * | 17.8x |
|---|---|---|---|---|---|
| Enterprise value | 393B 361B 348B 304B 566B 34,159B 622B 3,985B 1,510B 14,408B 1,473B 1,443B 58,265B | EV / Sales 2025 * |
4.36x | EV / Sales 2026 * | 4.03x |
| Free-Float |
77.08% | Yield 2025 * |
3.14% | Yield 2026 * | 3.29% |
More valuation ratios
* Estimated data
More news
Last Transcript: Johnson & Johnson
More recommendations
More press releases
| 1 day | -0.11% | ||
| 1 week | -2.33% | ||
| Current month | -1.34% | ||
| 1 month | +4.27% | ||
| 3 months | +11.04% | ||
| 6 months | -1.64% | ||
| Current year | +12.58% |
1 week
161.1
162.81
1 month
153.24
162.81
Current year
140.68
162.81
1 year
140.68
162.81
3 years
140.68
162.81
5 years
109.16
162.81
10 years
81.79
162.81
| Manager | Title | Age | Since |
|---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 62 | 2022-01-02 |
Joseph Wolk
DFI | Director of Finance/CFO | 58 | 2018-06-30 |
Penny M. Heaton
CTO | Chief Tech/Sci/R&D Officer | 60 | 2024-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Anne Mulcahy
BRD | Director/Board Member | 71 | 2009-10-22 |
Mark McClellan
BRD | Director/Board Member | 61 | 2013-10-14 |
Mary Beckerle
BRD | Director/Board Member | 70 | 2015-06-08 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 14.01% | 248 M€ | +9.31% | - | |
| 12.91% | 33 M€ | -5.28% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.11% | -2.33% | +2.93% | -7.57% | 392B | ||
| +1.48% | -6.45% | +7.86% | +195.32% | 731B | ||
| +0.10% | -1.18% | +19.05% | +35.85% | 374B | ||
| +0.99% | -11.28% | -41.35% | +53.21% | 343B | ||
| +0.89% | -0.39% | +32.50% | -15.10% | 277B | ||
| +0.94% | -0.65% | +16.51% | +27.83% | 240B | ||
| -0.15% | -0.08% | -22.18% | +20.26% | 239B | ||
| -0.60% | -4.53% | +12.51% | +21.00% | 215B | ||
| +0.34% | -3.43% | +16.68% | +35.48% | 169B | ||
| +0.47% | -3.78% | -7.95% | -50.74% | 146B | ||
| Average | +0.44% | -3.41% | +3.66% | +31.55% | 312.52B | |
| Weighted average by Cap. | +0.59% | -3.94% | +3.79% | +58.19% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 90.05B 82.77B 79.67B 69.71B 130B 7,829B 143B 913B 346B 3,302B 338B 331B 13,354B | 93.77B 86.2B 82.96B 72.6B 135B 8,153B 148B 951B 360B 3,439B 352B 344B 13,906B |
| Net income | 19.9B 18.29B 17.61B 15.41B 28.65B 1,730B 31.51B 202B 76.51B 730B 74.6B 73.09B 2,951B | 21.47B 19.74B 19B 16.62B 30.91B 1,867B 34B 218B 82.55B 787B 80.5B 78.87B 3,185B |
| Net Debt | 898M 826M 795M 695M 1.29B 78.09B 1.42B 9.11B 3.45B 32.94B 3.37B 3.3B 133B | -14.39B -13.23B -12.73B -11.14B -20.72B -1,251B -22.79B -146B -55.33B -528B -53.95B -52.86B -2,134B |
More financial data
* Estimated data
Employees
138,100
Sector
Pharmaceuticals
Calendar
Apr. 14
- Q1 2025 Earnings Release
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-03-14 | 162.81 $ | -0.11% | 6,235,797 |
| 25-03-13 | 162.99 $ | +0.09% | 5,286,734 |
| 25-03-12 | 162.85 $ | -1.81% | 8,010,692 |
| 25-03-11 | 165.86 $ | -1.10% | 9,890,648 |
| 25-03-10 | 167.70 $ | +0.61% | 17,558,982 |
Delayed Quote Nyse, March 14, 2025 at 04:00 pm EDT
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
162.81USD
Average target price
169.07USD
Spread / Average Target
+3.84%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- JNJ Stock